Clinical Trial

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-22
Trial Details
NCT Number NCT07438444
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 344 participants
Start Date 2026-02-27
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-19